Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Journal stats
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
TIGIT signaling restores suppressor function of Th1 Tregs
Liliana E. Lucca, Pierre-Paul Axisa, Emily R. Singer, Neal M. Nolan, Margarita Dominguez-Villar, David A. Hafler
Liliana E. Lucca, Pierre-Paul Axisa, Emily R. Singer, Neal M. Nolan, Margarita Dominguez-Villar, David A. Hafler
View: Text | PDF
Research Article Immunology

TIGIT signaling restores suppressor function of Th1 Tregs

  • Text
  • PDF
Abstract

Th1 Tregs are characterized by the acquisition of proinflammatory cytokine secretion and reduced suppressor activity. Th1 Tregs are found at increased frequency in autoimmune diseases, including type 1 diabetes and multiple sclerosis (MS). We have previously reported that in vitro stimulation with IL-12 recapitulates the functional and molecular features of MS-associated Th1 Tregs, revealing a central role for hyperactivation of the Akt pathway in their induction. TIGIT is a newly identified coinhibitory receptor that marks Tregs that specifically control Th1 and Th17 responses. Here, we report that signaling through TIGIT counteracts the action of IL-12 in inducing the Th1 program. Specifically, TIGIT signaling represses production of IFN-γ and T-bet expression and restores suppressor function in Tregs treated with IL-12. FoxO1 functional inhibition abolishes the protective effect of TIGIT, indicating that TIGIT signaling promotes FoxO1 nuclear localization. Consistent with this observation, signaling through TIGIT leads to a rapid suppression of Akt function and FoxO1 phosphorylation. Finally, TIGIT stimulation reduces the production of IFN-γ and corrects the suppressor defect of Tregs from patients with MS. Our results indicate an important role for TIGIT in controlling the functional stability of Tregs through repression of Akt, suggesting that the TIGIT pathway could be targeted for immunomodulatory therapies in human autoimmune disorders.

Authors

Liliana E. Lucca, Pierre-Paul Axisa, Emily R. Singer, Neal M. Nolan, Margarita Dominguez-Villar, David A. Hafler

×

Figure 3

TIGIT stimulation suppresses the Akt/FoxO1 pathway.

Options: View larger image (or click on image) Download as PowerPoint
TIGIT stimulation suppresses the Akt/FoxO1 pathway.
(A–C) Tregs stimulat...
(A–C) Tregs stimulated for the indicated times with αCD3+αCD28, IL-12, Fc-CD155, or isotype control. One representative experiment (A) and quantification of the delta between the indicated time points and the time 0 condition are shown (B, n = 7 for pAkt, and C, n = 5 for pFoxO1, paired t test with Bonferroni’s correction for multiple comparisons). (D–F) Sorted Tregs were rested in serum-free media for 2 hours and then fixed (ex vivo) or stimulated with αCD3+αCD28, IL-12, FcCD155, or isotype control overnight (16 hours). One representative experiment showing immunofluorescent staining for DAPI and FoxO1 (original magnification, ×63) (D) and quantification of the nuclear enrichment of FoxO1 for 2 donors (E and F, 2 outliers were removed [ROUT Q = 10%], unpaired t test, P < 0.0001; ex vivo = 16 cells, 16hstim = 80 cells, IgG1 = 80 cells, FcCD155 = 71 cells). *P < 0.05, **P < 0.005, ***P < 0.0005.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts